Corvus Pharmaceuticals, Inc.
CRVS
$3.24
$0.010.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.16M | 7.66M | 7.22M | 7.06M | 6.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.55M | 25.07M | 23.38M | 23.06M | 23.33M |
| Operating Income | -27.55M | -25.07M | -23.38M | -23.06M | -23.33M |
| Income Before Tax | -62.29M | -56.83M | -22.62M | -24.86M | -27.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.29 | -56.83 | -22.62 | -24.86 | -27.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.29M | -56.83M | -22.62M | -24.86M | -27.03M |
| EBIT | -27.55M | -25.07M | -23.38M | -23.06M | -23.33M |
| EBITDA | -27.46M | -24.98M | -23.28M | -22.95M | -23.18M |
| EPS Basic | -0.97 | -0.93 | -0.45 | -0.51 | -0.56 |
| Normalized Basic EPS | -0.60 | -0.58 | -0.28 | -0.32 | -0.35 |
| EPS Diluted | -0.97 | -0.93 | -0.45 | -0.51 | -0.56 |
| Normalized Diluted EPS | -0.60 | -0.58 | -0.28 | -0.32 | -0.35 |
| Average Basic Shares Outstanding | 243.80M | 224.49M | 206.76M | 194.55M | 192.06M |
| Average Diluted Shares Outstanding | 243.80M | 224.49M | 206.76M | 194.55M | 192.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |